vTv Therapeutics discovered TTP399 therapy for the treatment of patients with Type 1 diabetes.
TTP399 is a novel, oral, investigational once-daily glucokinase activator. It is considered to be an adjunctive therapy to insulin for the treatment of type 1 diabetes. Moreover, TTP399 shows a significant advantage over other type 1 diabetes therapies.
Low blood sugarlevel being the concern for both doctors and patients providers are apprehensive in utilizing tight glycemic control. Hence, TTP399 therapy offers a potential treatment to an unmet need in the diabetes community.
Type 1 diabetes is a serious, life threateningproblem affecting more than a millionday-to-day. Hypoglycemiais a leading cause of morbidity and potential mortality in the treatment of type 1 diabetes.
U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for TTP399 as an adjunctive therapy to insulin for the treatment of type 1 diabetes.
